No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
The Th17 inflammatory pathway therapeutic market is a subset of the larger immune disorder drugs market. It focuses on treatments that target the Th17 pathway, a subset of the immune system that is involved in the development of autoimmune diseases. These drugs are designed to reduce inflammation and improve the body's ability to fight off infection. They are used to treat a variety of conditions, including rheumatoid arthritis, psoriasis, and Crohn's disease.
The Th17 inflammatory pathway therapeutic market is a rapidly growing sector of the immune disorder drugs market. It is driven by the increasing prevalence of autoimmune diseases, as well as the development of new treatments that target the Th17 pathway. Companies in this market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more
